CAS: 49745-95-1; Dobutamine Hydrochloride

上下游产品

N-[1-methyl-3-(4-methoxyphenyl)propyl]-2-(3,4-dimethoxyphenyl)ethylamine hydr°Chloride

N-(2-(3,4-二甲氧基苯基)乙基)-4-甲氧基-α-甲基苯丙胺盐酸盐置于三氟化硼乙醚体系中,用 二氯甲烷 作为反应溶剂,化学反应 2.0H,以68.92%的收率获得产物盐酸多巴酚丁胺
参考文献:一种盐酸多巴酚丁胺的合成方法
标题:一种盐酸多巴酚丁胺的合成方法
摘要:本发明涉及原料药的合成,尤其涉及盐酸多巴酚丁胺的合成方法,该方法首先将茴香基丙酮,酸或酸加氢供体,催化剂和3,4‑二甲氧基苯乙胺,加入有机溶剂中混合,在30oc‑40°C,反应1~5小时;自然冷却至10~30°C,过滤;滤液用2%的氢氧化钠水溶液调节体系ph值至7‑8,分液水洗;有机相加入浓盐酸搅拌成盐,收集有机相,蒸馏;得到的浓缩物在有机溶剂中重结晶,真空干燥,得到中间体;得到的中间体在10‑20oc下,路易斯酸作用下脱甲基,接着在浓盐酸中成盐得到高纯度的盐酸多巴酚丁胺.本发明的优点在于克服现有技术的不足,提供一条全新的盐酸多巴酚丁胺的制备方法.该方法操作简单,合成路线短,对环境友好,收率高,成本低.

专利信息

专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-6030613-A
优先权日:1995-01-17
标题:Receptor specific transepithelial transport of therapeutics
发明人：BLUMBERG RICHARD S; SIMISTER NEIL E; LENCER WAYNE I
权利人:BRIGHAM & WOMENS HOSPITAL; UNIV BRANDEIS
摘要:The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

专利号:US-10814013-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

专利号:US-5776979-A
优先权日:1989-09-13
标 题 :Method of use of cardiotonic drugs and inhibitors of nitric oxide synthesis to alleviate pathologic hypotension
发明人：KILBOURN ROBERT G; GROSS STEVEN S; GRIFFITH OWEN W
权利人:UNIV TEXAS; CORNELL RES FOUNDATION INC
摘要:The present invention involves a method for prophylaxis or treatment of an animal for systemic hypotension induced by endotoxin and/or a biological response modifier such as the cytokines, IFN, TNF, IL-1 or IL-2 and the like. The method involves administering, preferably intravascularly, a therapeutically effective amount of dobutamine and an inhibitor of nitric oxide formation from arginine.

专利号:US-2008107598-A1
优先权日:2006-10-05
标 题:Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications

专利号:US-7547436-B2
优先权日:1995-01-17
标 题:Receptor specific transepithelial transport of therapeutics
发明人：BLUMBERG RICHARD S; LENCER WAYNE I; SIMISTER NEIL E
权利人:BRIGHAM & WOMENS HOSPITAL; UNIV BRANDEIS
摘要:The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.